Dashboard
Manage Tickers

ABBVAbbVie Inc.

NYSE abbvie.com


$ 166.42 $ 2.07 (1.26 %)    

Friday, 17-May-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 166.42
$ 165.35
$ 0.00 x 0
$ 0.00 x 0
$ 164.50 - $ 166.43
$ 125.85 - $ 181.20
4,951,883
na
295.06B
$ 0.64
$ 49.23
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-17-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-18-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-02-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 02-19-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-03-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-20-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion--analyst
AbbVie Is 'Successfully Positioned To Abso...
05/17/2024 17:47:16

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...

the-analyst-verdict-abbvie-in-the-eyes-of-5-experts
The Analyst Verdict: AbbVie In The Eyes Of...
05/17/2024 13:00:43

abbvie-says-it-will-present-new-data-supporting-leading-gastroenterology-portfolio-at-2024-digestive-disease-week-company-to-present-15-abstracts-including-three-oral-presentations-in-crohns-disease-and-ulcerative-colitis
AbbVie Says It Will Present New Data Suppo...
05/17/2024 11:34:26

The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.  Data to be...

cantor-fitzgerald-initiates-coverage-on-abbvie-with-overweight-rating-announces-price-target-of-200
Cantor Fitzgerald Initiates Coverage On Ab...
05/17/2024 11:16:23

Cantor Fitzgerald analyst Louise Chen initiates coverage on AbbVie (NYSE:ABBV) with a Overweight rating and announces Price ...

1000-invested-in-this-stock-5-years-ago-would-be-worth-2000-today
$1000 Invested In This Stock 5 Years Ago W...
05/16/2024 16:30:24

unpacking-the-latest-options-trading-trends-in-abbvie
Unpacking the Latest Options Trading Trend...
05/14/2024 17:31:06

abbvie-enters-into-collaboration-and-option-to-license-agreement-with-gilgamesh-pharmaceuticals-for-therapies-for-psychiatric-disorders
AbbVie Enters Into Collaboration And Optio...
05/13/2024 12:40:40

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop nex...

abbv---analyzing-abbvies-short-interest
(ABBV) - Analyzing AbbVie's Short Interest
05/10/2024 19:15:20

health-canada-approves-abbvies-qulipta-for-chronic-migraine-prevention-in-adults
Health Canada Approves AbbVie's QULIPTA Fo...
05/08/2024 12:05:24

1000-invested-in-this-stock-10-years-ago-would-be-worth-3100-today
$1000 Invested In This Stock 10 Years Ago ...
05/02/2024 18:30:17

Core News & Articles
CNBC Halftime Report Final Trades: Amazon....
04/30/2024 17:01:00

barclays-maintains-overweight-on-abbvie-lowers-price-target-to-187
Barclays Maintains Overweight on AbbVie, L...
04/29/2024 15:26:59

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $195 to $187.

peeling-back-the-layers-exploring-abbvie-through-analyst-insights
Peeling Back The Layers: Exploring AbbVie ...
04/29/2024 15:01:09

bmo-capital-maintains-outperform-on-abbvie-lowers-price-target-to-180
BMO Capital Maintains Outperform on AbbVie...
04/29/2024 14:09:17

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $19...

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

arthritis-patients---cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost
Arthritis Patients - Cigna's Evernorth To ...
04/26/2024 18:41:57

Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average ...

tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-whats-driving-markets-friday
Tech Stocks Rebound As Magnificent 7 Roar ...
04/26/2024 17:45:42

Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in...

ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-profit-outlook
Ex-Humira Growth Platform Drives AbbVie's ...
04/26/2024 13:54:00

AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immun...

abbvie-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-financial-results-and-raised-its-fy24-adjusted-eps-guidance-above-estimates
AbbVie shares are trading higher after the...
04/26/2024 11:43:06

abbvie-is-raising-its-2024-adjusted-eps-guidance-from-1097-1117-to-1113-1133-which-includes-an-unfavorable-impact-of-008-per-share-related-to-acquired-iprd-and-milestones-expense-versus-consensus-of-1112
AbbVie Is Raising Its 2024 Adjusted EPS Gu...
04/26/2024 11:38:57

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION